Horama

Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The funds will be mainly directed at developing Horama’s gene therapy for retinitis pigmentosa.  Published on 08/10/2017 Horama has raised a second fundraising round that will support […]

French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition.  A Phase I/II trial with Horama’s gene therapy for retinitis pigmentosa is running at the Nantes University Hospital. The therapy is aimed at fixing genetic defects in a […]

Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops gene therapies to treat genetic diseases affecting vision. The company will now start a Phase I/II clinical trial that will recruit 12 patients at the Nantes […]

Horama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M in its Series A round, which will speed up development of two candidates. Eye disorders are a popular indication for gene therapies, especially after the first gene therapy approvals – uniQure’s Glybera and GSK’s Strimvelis. Some other players in ophthalmologic […]